Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1990 Feb;61(2):298–302. doi: 10.1038/bjc.1990.56

Hormone levels in older women: a study of post-menopausal breast cancer patients and healthy population controls.

L Bernstein 1, R K Ross 1, M C Pike 1, J B Brown 1, B E Henderson 1
PMCID: PMC1971424  PMID: 2138030

Abstract

Hormone concentrations in blood and total 12 h urine values were compared between 40 post-menopausal women with breast cancer and 40 control women in a study which carefully controlled for the possible confounding effects of age, weight and pregnancy history by individually matching cases and controls on these factors. Breast cancer cases had received only surgical treatment for their localised disease, which was diagnosed from 1 to 9 years before hormonal evaluation. Cases had 15% higher serum oestradiol levels (P = 0.02), 40% more urinary oestradiol (P = 0.03) and 44% more urinary oestriol (P = 0.04) than control women. Cases also had higher levels of serum and urinary oestrone, but these differences were not statistically significant. The percentages of serum oestradiol not bound to albumin or sex-hormone binding globulin did not differ between cases and controls, nor were there statistically significant differences in the serum levels of prolactin, sex-hormone binding globulin or dehydroepiandrosterone sulphate. These results provide further support for the hypothesis that breast cancer risk is determined in part by post-menopausal serum oestrogen concentration.

Full text

PDF
298

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adami H. O., Johansson E. D., Vegelius J., Victor A. Serum concentrations of estrone, androstenedione, testosterone and sex-hormone-binding globulin in postmenopausal women with breast cancer and in age-matched controls. Ups J Med Sci. 1979;84(3):259–274. doi: 10.3109/03009737909179163. [DOI] [PubMed] [Google Scholar]
  2. Anderson D. C. Sex-hormone-binding globulin. Clin Endocrinol (Oxf) 1974 Jan;3(1):69–96. doi: 10.1111/j.1365-2265.1974.tb03298.x. [DOI] [PubMed] [Google Scholar]
  3. Argüelles A. E., Poggi U. L., Saborida C., Hoffman C., Chekherdemian M., Blanchard O. Endocrine profiles and breast cancer. Lancet. 1973 Jan 27;1(7796):165–168. doi: 10.1016/s0140-6736(73)90002-0. [DOI] [PubMed] [Google Scholar]
  4. Bernstein L., Depue R. H., Ross R. K., Judd H. L., Pike M. C., Henderson B. E. Higher maternal levels of free estradiol in first compared to second pregnancy: early gestational differences. J Natl Cancer Inst. 1986 Jun;76(6):1035–1039. [PubMed] [Google Scholar]
  5. Bernstein L., Pike M. C., Ross R. K., Judd H. L., Brown J. B., Henderson B. E. Estrogen and sex hormone-binding globulin levels in nulliparous and parous women. J Natl Cancer Inst. 1985 Apr;74(4):741–745. [PubMed] [Google Scholar]
  6. Bruning P. F., Bonfrèr J. M., Hart A. A. Non-protein bound oestradiol, sex hormone binding globulin, breast cancer and breast cancer risk. Br J Cancer. 1985 Apr;51(4):479–484. doi: 10.1038/bjc.1985.69. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. DeVane G. W., Czekala N. M., Judd H. L., Yen S. S. Circulating gonadotropins, estrogens, and androgens in polycystic ovarian disease. Am J Obstet Gynecol. 1975 Feb 15;121(4):496–500. doi: 10.1016/0002-9378(75)90081-2. [DOI] [PubMed] [Google Scholar]
  8. Drafta D., Schindler A. E., Milcu S. M., Keller E., Stroe E., Horodniceanu E., Bălănescu I. Plasma hormones in pre- and postmenopausal breast cancer. J Steroid Biochem. 1980 Jul;13(7):793–802. doi: 10.1016/0022-4731(80)90231-9. [DOI] [PubMed] [Google Scholar]
  9. Ehara Y., Siler T., VandenBerg G., Sinha Y. N., Yen S. S. Circulating prolactin levels during the menstrual cycle: episodic release and diurnal variation. Am J Obstet Gynecol. 1973 Dec 1;117(7):962–970. doi: 10.1016/0002-9378(73)90069-0. [DOI] [PubMed] [Google Scholar]
  10. England P. C., Skinner L. G., Cottrell K. M., Sellwood R. A. Serum oestradiol-17 beta in women with benign and malignant breast disease. Br J Cancer. 1974 Dec;30(6):571–576. doi: 10.1038/bjc.1974.237. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Grattarola R., Secreto G., Recchione C., Castellini W. Androgens in breast cancer. II. Endometrial adenocarcinoma and breast cancer in married postmenopausal women. Am J Obstet Gynecol. 1974 Jan 15;118(2):173–178. [PubMed] [Google Scholar]
  12. Grönroos M., Aho A. J. Estrogen metabolism in postmenopausal women with primary and recurrent breast cancer. Eur J Cancer. 1968 Oct;4(5):523–527. doi: 10.1016/0014-2964(68)90008-x. [DOI] [PubMed] [Google Scholar]
  13. Henderson B. E., Ross R., Bernstein L. Estrogens as a cause of human cancer: the Richard and Hinda Rosenthal Foundation award lecture. Cancer Res. 1988 Jan 15;48(2):246–253. [PubMed] [Google Scholar]
  14. Hisserich J. C., Martin S. P., Henderson B. E. An areawide cancer reporting network. Public Health Rep. 1975 Jan-Feb;90(1):15–17. [PMC free article] [PubMed] [Google Scholar]
  15. Key T. J., Pike M. C. The role of oestrogens and progestagens in the epidemiology and prevention of breast cancer. Eur J Cancer Clin Oncol. 1988 Jan;24(1):29–43. doi: 10.1016/0277-5379(88)90173-3. [DOI] [PubMed] [Google Scholar]
  16. Langley M. S., Hammond G. L., Bardsley A., Sellwood R. A., Anderson D. C. Serum steroid binding proteins and the bioavailability of estradiol in relation to breast diseases. J Natl Cancer Inst. 1985 Nov;75(5):823–829. doi: 10.1093/jnci/75.5.823. [DOI] [PubMed] [Google Scholar]
  17. Lobo R. A., Paul W. L., Goebelsmann U. Dehydroepiandrosterone sulfate as an indicator of adrenal androgen function. Obstet Gynecol. 1981 Jan;57(1):69–73. [PubMed] [Google Scholar]
  18. Lubin F., Ruder A. M., Wax Y., Modan B. Overweight and changes in weight throughout adult life in breast cancer etiology. A case-control study. Am J Epidemiol. 1985 Oct;122(4):579–588. doi: 10.1093/oxfordjournals.aje.a114137. [DOI] [PubMed] [Google Scholar]
  19. MARMORSTON J., CROWLEY L. G., MYERS S. M., STERN E., HOPKINS C. E. II. URINARY EXCRETION OF ESTRONE, ESTRADIOL, AND ESTRIOL BY PATIENTS WITH BREAST CANCER AND BENIGN BREAST DISEASE. Am J Obstet Gynecol. 1965 Jun 15;92:460–467. doi: 10.1016/s0002-9378(16)34835-9. [DOI] [PubMed] [Google Scholar]
  20. Malarkey W. B., Schroeder L. L., Stevens V. C., James A. G., Lanese R. R. Twenty-four-hour preoperative endocrine profiles in women with benign and malignant breast disease. Cancer Res. 1977 Dec;37(12):4655–4659. [PubMed] [Google Scholar]
  21. McFadyen I. J., Forrest A. P., Prescott R. J., Golder M. P., Groom G. V., Fahmy D. R., Griffiths K. Circulating hormone concentrations in women with breast cancer. Lancet. 1976 May 22;1(7969):1100–1102. doi: 10.1016/s0140-6736(76)90064-7. [DOI] [PubMed] [Google Scholar]
  22. Moore J. W., Clark G. M., Bulbrook R. D., Hayward J. L., Murai J. T., Hammond G. L., Siiteri P. K. Serum concentrations of total and non-protein-bound oestradiol in patients with breast cancer and in normal controls. Int J Cancer. 1982 Jan 15;29(1):17–21. doi: 10.1002/ijc.2910290105. [DOI] [PubMed] [Google Scholar]
  23. Moore J. W., Clark G. M., Hoare S. A., Millis R. R., Hayward J. L., Quinlan M. K., Wang D. Y., Bulbrook R. D. Binding of oestradiol to blood proteins and aetiology of breast cancer. Int J Cancer. 1986 Nov 15;38(5):625–630. doi: 10.1002/ijc.2910380502. [DOI] [PubMed] [Google Scholar]
  24. Morreal C. E., Dao T. L., Nemoto T., Lonergan P. A. Urinary excretion of estrone, estradiol, and estriol in postmenopausal women with primary breast cancer. J Natl Cancer Inst. 1979 Nov;63(5):1171–1174. [PubMed] [Google Scholar]
  25. Musey V. C., Collins D. C., Musey P. I., Martino-Saltzman D., Preedy J. R. Long-term effect of a first pregnancy on the secretion of prolactin. N Engl J Med. 1987 Jan 29;316(5):229–234. doi: 10.1056/NEJM198701293160501. [DOI] [PubMed] [Google Scholar]
  26. Ota D. M., Jones L. A., Jackson G. L., Jackson P. M., Kemp K., Bauman D. Obesity, non-protein-bound estradiol levels, and distribution of estradiol in the sera of breast cancer patients. Cancer. 1986 Feb 1;57(3):558–562. doi: 10.1002/1097-0142(19860201)57:3<558::aid-cncr2820570326>3.0.co;2-1. [DOI] [PubMed] [Google Scholar]
  27. PERSSON B. H., RISHOLM L. OOPHORECTOMY AND CORTISONE TREATMENT AS A METHOD OF ELIMINATING OESTROGEN PRODUCTION IN PATIENTS WITH BREAST CANCER. Acta Endocrinol (Copenh) 1964 Sep;47:15–26. doi: 10.1530/acta.0.0470015. [DOI] [PubMed] [Google Scholar]
  28. Pardridge W. M., Mietus L. J. Transport of steroid hormones through the rat blood-brain barrier. Primary role of albumin-bound hormone. J Clin Invest. 1979 Jul;64(1):145–154. doi: 10.1172/JCI109433. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Pardridge W. M. Serum bioavailability of sex steroid hormones. Clin Endocrinol Metab. 1986 May;15(2):259–278. doi: 10.1016/s0300-595x(86)80024-x. [DOI] [PubMed] [Google Scholar]
  30. Reed M. J., Beranek P. A., Cheng R. W., Ghilchik M. W., James V. H. The distribution of oestradiol in plasma from postmenopausal women with or without breast cancer: relationships with metabolic clearance rates of oestradiol. Int J Cancer. 1985 Apr 15;35(4):457–460. doi: 10.1002/ijc.2910350407. [DOI] [PubMed] [Google Scholar]
  31. Reed M. J., Cheng R. W., Noel C. T., Dudley H. A., James V. H. Plasma levels of estrone, estrone sulfate, and estradiol and the percentage of unbound estradiol in postmenopausal women with and without breast disease. Cancer Res. 1983 Aug;43(8):3940–3943. [PubMed] [Google Scholar]
  32. Rosner W. A simplified method for the quantitative determination of testosterone-estradiol-binding globulin activity in human plasma. J Clin Endocrinol Metab. 1972 Jun;34(6):983–988. doi: 10.1210/jcem-34-6-983. [DOI] [PubMed] [Google Scholar]
  33. Ross R. K., Paganini-Hill A., Gerkins V. R., Mack T. M., Pfeffer R., Arthur M., Henderson B. E. A case-control study of menopausal estrogen therapy and breast cancer. JAMA. 1980 Apr 25;243(16):1635–1639. [PubMed] [Google Scholar]
  34. Secreto G., Recchione C., Cavalleri A., Miraglia M., Dati V. Circulating levels of testosterone, 17 beta-oestradiol, luteinising hormone and prolactin in postmenopausal breast cancer patients. Br J Cancer. 1983 Feb;47(2):269–275. doi: 10.1038/bjc.1983.35. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Seymour-Munn K., Adams J. Estrogenic effects of 5-androstene-3 beta, 17 beta-diol at physiological concentrations and its possible implication in the etiology of breast cancer. Endocrinology. 1983 Feb;112(2):486–491. doi: 10.1210/endo-112-2-486. [DOI] [PubMed] [Google Scholar]
  36. Siiteri P. K., Simberg N., Murai J. Estrogens and breast cancer. Ann N Y Acad Sci. 1986;464:100–105. doi: 10.1111/j.1749-6632.1986.tb15997.x. [DOI] [PubMed] [Google Scholar]
  37. Thijssen J. H., Poortman J., Schwarz F. Androgens in postmenopausal breast cancer: excretion, production and interaction with estrogens. J Steroid Biochem. 1975 May;6(5):729–734. doi: 10.1016/0022-4731(75)90060-6. [DOI] [PubMed] [Google Scholar]
  38. Trichopoulos D., MacMahon B., Cole P. Menopause and breast cancer risk. J Natl Cancer Inst. 1972 Mar;48(3):605–613. [PubMed] [Google Scholar]
  39. Wang D. Y., Hayward J. L., Bulbrook R. D., Kumaoka S., Takatani O., Abe O., Utsunomiya J. Plasma dehydroepiandrosterone and androsterone sulphates, androstenedione and urinary androgen metabolites in normal British and Japanese women. Eur J Cancer. 1976 Dec;12(12):951–958. doi: 10.1016/0014-2964(76)90060-8. [DOI] [PubMed] [Google Scholar]
  40. Wysowski D. K., Comstock G. W., Helsing K. J., Lau H. L. Sex hormone levels in serum in relation to the development of breast cancer. Am J Epidemiol. 1987 May;125(5):791–799. doi: 10.1093/oxfordjournals.aje.a114596. [DOI] [PubMed] [Google Scholar]
  41. Yu M. C., Gerkins V. R., Henderson B. E., Brown J. B., Pike M. C. Elevated levels of prolactin in nulliparous women. Br J Cancer. 1981 Jun;43(6):826–831. doi: 10.1038/bjc.1981.121. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES